Spots Global Cancer Trial Database for recurrent multiple myeloma

Every month we try and update this database with for recurrent multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	NCT03389347	Plasma Cell Leu... Recurrent Multi... Refractory Mult...	Biospecimen Col... High Throughput... Laboratory Biom...	18 Years -	University of Washington
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	NCT06232044	Recurrent Multi... Refractory Mult...	Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Alliance for Clinical Trials in Oncology
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma	NCT02481934	Multiple Myelom...	NKAE cells infu... Lenalidomide Bortezomib	20 Years - 80 Years	Hospital Universitario 12 de Octubre
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment	NCT03770260	Recurrent Multi... Refractory Mult...	Ixazomib Citrat... Pevonedistat	18 Years -	National Cancer Institute (NCI)
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	NCT04764942	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Mayo Clinic
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT05950113	Recurrent Multi... Refractory Mult...	Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Fludeoxyglucose... Immunotherapy Leukapheresis Magnetic Resona... Positron Emissi...	18 Years - 74 Years	Jonsson Comprehensive Cancer Center
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma	NCT05847569	Recurrent Multi... Refractory Mult...	Belantamab Mafo... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Positron Emissi...	18 Years -	Mayo Clinic
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	NCT03031730	Plasmacytoma Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin	18 Years -	National Cancer Institute (NCI)
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	NCT04764942	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Mayo Clinic
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	NCT05981209	Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dexamethasone Echocardiograph... Elotuzumab Magnetic Resona... Mezigdomide X-Ray Imaging	18 Years -	Ohio State University Comprehensive Cancer Center
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT02101944	Anemia Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Laboratory Biom... Pelareorep	18 Years -	National Cancer Institute (NCI)
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma	NCT02481934	Multiple Myelom...	NKAE cells infu... Lenalidomide Bortezomib	20 Years - 80 Years	Hospital Universitario 12 de Octubre
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	NCT06232044	Recurrent Multi... Refractory Mult...	Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Alliance for Clinical Trials in Oncology
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT02101944	Anemia Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Laboratory Biom... Pelareorep	18 Years -	National Cancer Institute (NCI)
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	NCT03031730	Plasmacytoma Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin	18 Years -	National Cancer Institute (NCI)
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma	NCT03798678	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Telaglenastat H...	18 Years -	National Cancer Institute (NCI)
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients	NCT03618602	Refractory Mult... Recurrent Multi...	Bisthianostat	18 Years - 70 Years	Shanghai Theorion Pharmaceutical Co Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: